marked.bio

Nectin-4 ADC · ADC

enfortumab vedotin

5 active trials across 4 of our biomarkers, targeting Nectin-4. Not approved for any biomarker on marked.bio yet.

Also known as Padcev.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 2 Phase 2
FGFR3 alteration (mutation or fusion) 2 2 Phase 1
EGFR exon 19 deletion / L858R 1 1 Phase 1/2
FGFR2 fusion or rearrangement 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of enfortumab vedotin.

  1. Convalife 1
  2. Eli Lilly 1

Trials

5 of 5 trials shown

  1. Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

    Not yet recruiting Phase 2 Northwestern University Starts 2027Primary completion 2030-05 NCT07863765

    enfortumab vedotin

    For BRAF V600E mutated: 2 lines as TKIs and ≥ 1 line of immunotherapy allowed

    BRAF V600EMetastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma

  2. CVL006 Combination Therapy in Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Convalife Started 2025Primary completion 2028-08 NCT07157956

    pemetrexedcarboplatinsacituzumab tirumotecantrastuzumab deruxtecanenfortumab vedotin

    …rm2.1, Arm2.2, Arm2.5 and Arm2.7: For NSCLC Arm2.1: Non-squamous, wild-type NSCLC Arm2.2: EGFRm nsqNSCLC Arm2.3: Malignant pleural mesothelioma Arm2.4: triple-negative breast cancer Arm…

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor

  3. PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

    Active, not recruiting Phase 2 Grupo Español Multidisciplinar de Melanoma Started 2025Primary completion 2027-06 NCT06906822

    enfortumab vedotinpembrolizumab

    BRAF mutated patients should have received BRAF/MEK inhibitors and PD1/PDL1 therapy c.

    BRAF V600EMelanoma

  4. FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

    Recruiting Phase 1 Eli Lilly Started 2023Primary completion 2027-06 NCT05614739

    Vepugratinibpembrolizumabenfortumab vedotintrastuzumab deruxtecanmidazolamDigoxinRosuvastatin

    …, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.

    FGFR3 alteration (mutation or fusion)Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

  5. Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2022Primary completion 2026-12 NCT04963153

    enfortumab vedotinerdafitinib FDA EU

    …ith Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementLocally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma